Lifecore Biomedical, Inc. - Common Stock's Return On Capital Employed Insights
Lifecore Biomedical, Inc. - Common Stock's Return On Capital Employed Insights
Benzinga Pro data, Lifecore Biomedical, Inc. - Common Stock (NASDAQ:LFCR) reported Q2 sales of $38.80 million. Earnings fell to a loss of $12.45 million, resulting in a 3.19% decrease from last quarter. In Q1, Lifecore Biomedical, Inc. - Common Stock brought in $43.35 million in sales but lost $12.06 million in earnings.
What Is ROCE?
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Lifecore Biomedical, Inc. - Common Stock posted an ROCE of -0.17%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Lifecore Biomedical, Inc. - Common Stock is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
For Lifecore Biomedical, Inc. - Common Stock, a negative ROCE ratio of -0.17% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
Analyst Predictions
Lifecore Biomedical, Inc. - Common Stock reported Q2 earnings per share at $-0.24/share, which did not meet analyst predictions of $0.03/share.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Benzinga Pro data, Lifecore Biomedical, Inc. - Common Stock (NASDAQ:LFCR) reported Q2 sales of $38.80 million. Earnings fell to a loss of $12.45 million, resulting in a 3.19% decrease from last quarter. In Q1, Lifecore Biomedical, Inc. - Common Stock brought in $43.35 million in sales but lost $12.06 million in earnings.
使用臨數據, 力科生物醫藥股份有限公司-普通股 納斯達克：LFCR）報告第二季度的銷售額為 3,880 萬美元。盈利下降至 1245 萬美元的虧損，較上一季度減少 3.19%。在第一季度，生物醫學公司-普通股帶來了 4,335 萬美元的銷售額，但損失了 1206 萬美元的收益。
What Is ROCE?
什麼是強制性行為？
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Lifecore Biomedical, Inc. - Common Stock posted an ROCE of -0.17%.
受僱資本回報率是一種衡量稅前利潤相對於企業所僱用的資本的年度稅前利潤。盈利和銷售額的變化表明公司 ROCE 的變化。較高的 ROCE 通常代表公司的成功增長，並且是未來每股收益較高的標誌。低或負 ROCE 表明相反。在第二季度，生物醫學公司-普通股發布了 -0.17％ 的 ROCE。
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
請記住，雖然 ROCE 是衡量公司近期業績的一個很好的衡量標準，但它並不是公司在不久的將來盈利或銷售額的高度可靠預測指標。
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Lifecore Biomedical, Inc. - Common Stock is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
ROCE 是一個有力的指標，用於比較同類公司的資本分配的有效性。一個相對較高的 ROCE 顯示 Lifeore 生物醫學公司-普通股潛在的效率比其他公司在其行業更高的水平上運行。如果公司以目前的資本水平產生高額利潤，那麼其中一些資金可以再投資於更多的資本，這通常會導致更高的回報，並最終導致每股收益（EPS）增長。
For Lifecore Biomedical, Inc. - Common Stock, a negative ROCE ratio of -0.17% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
對於 Lifeore 生物醫學公司-普通股，負 ROCE 比率為 -0.17％ 表明管理層可能無法有效地分配其資本。有效的資本分配是一個積極的指標，一個公司將取得更持久的成功和有利的長期回報; 不良的資本分配可能會隨著時間的推移對公司的業績產生水蛭。
Analyst Predictions
分析師預測
Lifecore Biomedical, Inc. - Common Stock reported Q2 earnings per share at $-0.24/share, which did not meet analyst predictions of $0.03/share.
生物醫學股份有限公司-普通股報告第二季度每股收益為 0.24 美元/股，這並不符合 0.03 美元/股的分析師預測。
This article was generated by Benzinga's automated content engine and reviewed by an editor.
本文由 Beninga 的自動化內容引擎生成，並由編輯審查。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧